PRP vs PRF in Management of Striae Distensae

NCT07561671 | Completed

• 1 other identifier: 11345-3-12-2023
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

A split-side comparative clinical study evaluating the efficacy and safety of injectable platelet-rich fibrin (PRF) versus platelet-rich plasma (PRP), alone or combined with microneedling, in the treatment of striae distensae. Thirty patients received PRF or PRP on one side and combination therapy with microneedling on the contralateral side over five sessions. Outcomes included striae width, length, severity score, and patient satisfaction

Conditions

Striae Distensae

Outcome Measures

Primary Outcomes (2)

• The Imam, Nelva, Alviera score (INA score) (Change in striae severity)

  The INA score ranges from 0 to 54, with higher scores indicating greater striae distensae severity, therefore representing a worse outcome. Severity was categorized as mild for scores \<21, moderate for scores 21-40, and severe for scores \>40.

  baseline to 1 month after last session

• Change in striae severity (Imam, Nelva, Alviera score (INA score)

  The INA score ranges from 0 to 54, with higher scores indicating greater striae distensae severity, therefore representing a worse outcome. Severity was categorized as mild for scores \<21, moderate for scores 21-40, and severe for scores \>40.

  1 month after last session

Study Arms (4)

PRF

ACTIVE COMPARATOR

Intradermal injection of platelet-rich fibrin

Biological: PRF group

PRF and Microneedling

ACTIVE COMPARATOR

Microneedling followed by topical PRF application

Device: PRF and microneedling

PRP

ACTIVE COMPARATOR

Intradermal injection of platelet-rich plasma

Biological: PRP injection

PRP and microneedling

ACTIVE COMPARATOR

Device: PRP and microneedling

Interventions

PRP and microneedling DEVICE

Performed using a dermapen device with 1 mm needle depth, followed by topical application of PRP.

PRP and microneedling

PRF and microneedling DEVICE

Performed using a dermapen device with 1 mm needle depth, followed by topical application of PRF.

PRF and Microneedling

PRF group BIOLOGICAL

Autologous platelet-rich fibrin prepared via single-spin centrifugation without anticoagulant and injected intradermally

PRF

PRP injection BIOLOGICAL

Intradermal injection of platelet-rich plasma

PRP

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults ≥18 years
• Presence of striae distensae (rubrae or alba)
• Willingness to participate and provide informed consent

You may not qualify if:

• Keloid or hypertrophic scar tendency
• Bleeding disorders or anticoagulant use
• Pregnancy
• Active skin infections (e.g., herpes, impetigo, tinea)
• History of malignancy or collagen disease
• Use of antineoplastic drugs
• Conditions impairing wound healing
• Unrealistic expectations

Sponsors & Collaborators

• Zagazig University: lead

Study Sites (1)

Zagazig University Hospitals

Zagazig, Zagazig--, 44519, Egypt

Location

MeSH Terms

Conditions

Striae Distensae

Interventions

Percutaneous Collagen Induction

Condition Hierarchy (Ancestors)

Skin Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Complementary Therapies; Therapeutics; Physical Therapy Modalities; Punctures; Rehabilitation

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr

Study Record Dates

• First Submitted: April 25, 2026
• First Posted: May 1, 2026
• Study Start: February 2, 2024
• Primary Completion: September 25, 2025
• Study Completion: February 17, 2026
• Last Updated: May 7, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)